Serenoa repens (Saw Palmetto)

Saw palmetto (Serenoa repens) is a palm native to the southeastern United States whose berry extract contains fatty acids, sterols, and polysaccharides that inhibit 5-alpha-reductase, the enzyme converting testosterone to dihydrotestosterone (DHT). This inhibition is the primary proposed mechanism behind its traditional and investigated use in supporting urinary tract function in men with benign prostatic hyperplasia (BPH).

Origin & History

Serenoa repens (saw palmetto) extracts are obtained by solvent extraction of dried saw palmetto fruit. Three primary commercial extraction processes exist: ethanolic, hexanic (n-hexane), and supercritical carbon dioxide (sCO₂), each producing chemically non-equivalent products with distinct compositions.

Historical & Cultural Context

No information about traditional or historical use of Serenoa repens was included in the provided research sources.

Health Benefits

• No specific health benefits can be cited from the provided research dossier
• The available sources only describe extraction methods and chemical composition differences
• No clinical evidence or health outcome data was included in the research
• No pharmacological effects or therapeutic applications were documented
• Further clinical research would be needed to establish evidence-based health benefits

How It Works

Saw palmetto berry extract inhibits both type I and type II isoforms of 5-alpha-reductase, reducing the conversion of testosterone to the more potent androgen dihydrotestosterone (DHT) in prostatic tissue. The liposterolic fraction—comprising free fatty acids such as oleic, lauric, and myristic acid, alongside phytosterols including beta-sitosterol—is considered responsible for anti-androgenic and potential anti-inflammatory effects mediated partly through inhibition of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways. Some evidence also suggests alpha-1 adrenergic receptor antagonism, which may contribute to smooth muscle relaxation in the bladder neck and prostate.

Scientific Research

The provided research dossier contains no clinical trials, randomized controlled trials, or meta-analyses. No PubMed PMIDs were included in the available sources.

Clinical Summary

The European Medicines Agency (EMA) has established a well-established medicinal use monograph for Serenoa repens dry extract (standardized liposterolic extract) in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Multiple randomized controlled trials, including studies with sample sizes ranging from 85 to over 1,000 participants, have examined standardized extracts (typically 160 mg twice daily or 320 mg once daily) against placebo and active comparators such as tamsulosin and finasteride. Evidence indicates modest but clinically meaningful improvements in urinary flow rate (Qmax) and International Prostate Symptom Score (IPSS), though some large RCTs, including the STEP and CAMUS trials, found no significant superiority over placebo for moderate-to-severe BPH. Overall evidence is rated as moderate quality, with the extract performing more consistently in mild-to-moderate symptom presentations.

Nutritional Profile

Serenoa repens (Saw Palmetto) berry extract is characterized primarily by its liposterolic fraction rather than conventional macronutrients. Fatty acids constitute 70-95% of the lipophilic extract, with lauric acid (C12:0) typically representing the dominant fatty acid at approximately 25-30% of total fatty acids, followed by oleic acid (C18:1) at 25-30%, myristic acid (C14:0) at 10-14%, palmitic acid (C16:0) at 8-11%, linoleic acid (C18:2) at 3-7%, and caprylic/capric acids (C8:C10) at smaller fractions. Free fatty acids and their ethyl esters are the primary bioactive lipid forms. Phytosterols are present at approximately 0.1-0.3% of the lipophilic extract, predominantly beta-sitosterol, campesterol, stigmasterol, and cycloartenol. Polyphenolic compounds including flavonoids (isoquercitrin, rutin) and hydroxycinnamic acid derivatives are present in the hydrophilic fraction at trace concentrations. Aliphatic alcohols including 1-octacosanol and 1-triacontanol contribute to the minor lipid fraction. The dried berry contains approximately 1-2% total lipids in whole fruit form; commercial extracts are typically standardized to 85-95% fatty acids and sterols. Bioavailability of lipophilic components is enhanced by co-administration with dietary fat. Conventional macronutrients (protein, digestible carbohydrates, dietary fiber) are not therapeutically relevant fractions in commercial preparations.

Preparation & Dosage

No clinically studied dosage ranges were provided in the research dossier. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Cannot be determined from available research

Safety & Interactions

Saw palmetto is generally well tolerated; the most commonly reported adverse effects are mild gastrointestinal complaints including nausea, abdominal pain, and diarrhea, which can be minimized by taking it with food. Due to its anti-androgenic mechanism, saw palmetto may theoretically interact with hormonal therapies including testosterone replacement, estrogen-containing contraceptives, and 5-alpha-reductase inhibitor drugs such as finasteride or dutasteride, potentially producing additive or antagonistic effects. It may also potentiate anticoagulant and antiplatelet medications (e.g., warfarin, aspirin, clopidogrel) due to inhibitory effects on arachidonic acid metabolism, increasing bleeding risk. Its use is contraindicated during pregnancy and breastfeeding due to potential hormonal activity, and it should not be used in individuals under 18 without medical supervision.